Title: hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable
pancreatic cancer patients
Version: 0 Date: 09 Dec 2022
Reviewer's report:
In the present study entitled “hENT1’s role in adjuvant intra-arterial gemcitabine-based
chemotherapy for resectable pancreatic cancer patients“, the authors have evaluated the clinical
significance of hENT1 as a prognostic predictor for pancreatic cancer patients. They concluded
that high expression of hENT1 is a positive prognostic factor for adjuvant intra-arterial
gemcitabine-based chemotherapy in resectable pancreatic cancer. The objective addressed here
is relevant and clinically important.
I have several comments for the authors:
1. All patients received gemcitabine for adjuvant chemotherapy, but the dosing regimens were
not consistent among individuals (Page 7). The authors should clarify the dosing regimens in
Table 1. If there were significant differences in the dosing regimens between the high and low
groups, it could be a major bias and contribute to survival.
2. In the multivariate analysis, the authors included some factors that were not significantly
related to survival. The insignificant factors in the univariate analysis should not be included in
the multivariate analysis, because they could lead to wrong results.
Title: hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable
pancreatic cancer patients
Version: 0 Date: 09 Dec 2022
Reviewer's report:
In the present study entitled “hENT1’s role in adjuvant intra-arterial gemcitabine-based
chemotherapy for resectable pancreatic cancer patients“, the authors have evaluated the clinical
significance of hENT1 as a prognostic predictor for pancreatic cancer patients. They concluded
that high expression of hENT1 is a positive prognostic factor for adjuvant intra-arterial
gemcitabine-based chemotherapy in resectable pancreatic cancer. The objective addressed here
is relevant and clinically important.
I have several comments for the authors:
1. All patients received gemcitabine for adjuvant chemotherapy, but the dosing regimens were
not consistent among individuals (Page 7). The authors should clarify the dosing regimens in
Table 1. If there were significant differences in the dosing regimens between the high and low
groups, it could be a major bias and contribute to survival.
2. In the multivariate analysis, the authors included some factors that were not significantly
related to survival. The insignificant factors in the univariate analysis should not be included in
the multivariate analysis, because they could lead to wrong results.
Please review this paper.
user
Title: hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable
pancreatic cancer patients
Version: 0 Date: 09 Dec 2022
Reviewer's report:
In the present study entitled “hENT1’s role in adjuvant intra-arterial gemcitabine-based
chemotherapy for resectable pancreatic cancer patients“, the authors have evaluated the clinical
significance of hENT1 as a prognostic predictor for pancreatic cancer patients. They concluded
that high expression of hENT1 is a positive prognostic factor for adjuvant intra-arterial
gemcitabine-based chemotherapy in resectable pancreatic cancer. The objective addressed here
is relevant and clinically important.
I have several comments for the authors:
1. All patients received gemcitabine for adjuvant chemotherapy, but the dosing regimens were
not consistent among individuals (Page 7). The authors should clarify the dosing regimens in
Table 1. If there were significant differences in the dosing regimens between the high and low
groups, it could be a major bias and contribute to survival.
2. In the multivariate analysis, the authors included some factors that were not significantly
related to survival. The insignificant factors in the univariate analysis should not be included in
the multivariate analysis, because they could lead to wrong results.
assistant